Chronic kidney disease (CKD) is a progressive loss of kidney function that is common in older cats. Although renal diets and treatments for proteinuria, hypertension, dehydration and other complications can improve outcomes, they generally manage consequences of kidney dysfunction rather than restore lost renal function. Long-term care may also require multiple medications or frequent dosing, creating challenges for cats and caregivers. There is a need for practical treatments that slow, halt or potentially reverse progression, ideally from early stages.
Early detection represents another important challenge. Creatinine can rise late and is affected by muscle mass; symmetric dimethylarginine (SDMA) can detect reduced filtration earlier but is not specific to CKD. Urine protein, urine concentration and imaging provide additional clues, yet may be variable, nonspecific or inconclusive in early disease. Novel, validated biomarkers could more reliably identify early CKD, distinguish it from other renal abnormalities and help guide intervention.
Additionally, access to reliable feline-specific in vitro and in vivo CKD models remains a challenge for research and therapeutic development. More representative models could facilitate understanding of disease mechanisms and support evaluation of emerging treatments.
Addressing these interconnected gaps could advance the detection, study and treatment of feline CKD.
We are looking for innovative solutions to advance the treatment, early detection, and study of feline chronic kidney disease (CKD). Our ultimate goal is to identify and bring to market disease-modifying therapeutics capable of slowing, halting, or potentially reversing CKD progression.
We are also interested in novel biomarkers enabling earlier and more specific disease detection, particularly at International Renal Interest Society (IRIS) stages 1–2, as well as in vitro and in vivo models that support CKD research and therapeutic development. For biomarkers and disease models, we welcome collaborations with experts whose approaches have been explored in other species and could potentially be adapted to cats, even if feline-specific validation has not yet been conducted.